Navigation Links
MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
Date:1/31/2008

VANCOUVER and SAN DIEGO, Jan. 31 /PRNewswire-FirstCall/ - MIGENIX Inc. (TSX: MGI, OTC: MGIFF), a clinical-stage developer of drugs for infectious diseases, will add a 600mg celgosivir combination therapy arm to its currently enrolling Phase II viral kinetics study in hepatitis C virus ("HCV") treatment-naive patients. The protocol amendment to this study has received Health Canada and Institutional Review Board (IRB) approvals. The purpose of this new treatment arm is to assess 600mg celgosivir (an oral alpha glucosidase I inhibitor) for tolerability, pharmacokinetics and viral kinetics when combined with the standard of care drugs, pegylated interferon plus ribavirin, as compared to the standard of care drugs alone and to 400mg celgosivir plus the standard of care for up to 12 weeks of therapy.

AnnKatrin Petersen, M.D., VP Clinical Development for MIGENIX commented, "The favorable tolerability experienced to date with 400mg per day of celgosivir in triple combination with pegylated interferon plus ribavirin, along with the clinically significant benefit demonstrated in our previous non-responder study, gives us confidence that increasing the dose to 600mg per day in combination therapy is an important development step for the optimization and advancement of celgosivir."

The currently enrolling Phase II viral kinetics study is a 12-week randomized, active-controlled study initially planned to enroll up to 20 patients in two treatment arms: (i) celgosivir (400mg once daily) plus peginterferon alfa-2b plus ribavirin ("PRC"); and (ii) peginterferon alfa-2b plus ribavirin ("PR"). Tolerability, pharmacokinetics and viral kinetics are being evaluated in the trial. The approved protocol amendment allows for the addition of a 600mg once daily dosing arm and the flexibility to increase the total number of patients in the study up to 50. With 15 patients enrolled to date, it is planned that approximately six additional patients will be enrolled, all in th
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results
2. MIGENIX Second Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
3. MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
5. MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting
6. MIGENIX First Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
7. Dey L.P. and Critical Therapeutics Launch Twice-Daily ZYFLO CR(TM) (Zileuton) Extended-Release Tablets for the Chronic Treatment of Asthma
8. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
9. Oncolytics Biotech Inc. Proceeds to Full Enrolment in U.S. Phase II Sarcoma Clinical Trial
10. Phase 1 Studies Show Promise of QuatRxs Novel Compound, Sobetirome, for Lowering LDL Cholesterol Levels
11. Surface Logix Achieves Objectives With SLx-4090 in Phase 2a Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Hartford, CT (PRWEB) July 30, 2014 ... economic development organization based in East Hartford, Conn., was ... on Phase II of a project that will determine ... facility in rural north-central Connecticut. USDA Rural Development provided ... (RBEG) program for the second phase of the feasibility ...
(Date:7/30/2014)... Arlington, MA (PRWEB) July 30, 2014 ... products, announces completion of its first round of seed ... round will enable preliminary efforts to develop a novel ... the support of our investors and their commitment to ... CEO of LayerBio. "Ophthalmology is one of many areas ...
(Date:7/29/2014)... The advanced optical methods and applications for ... a revolution in the neurosciences were the inspiration behind ... SPIE, the international society for optics and photonics ... of the BRAIN Initiative in the United States, and ... vision for and provide examples of the impact that ...
(Date:7/29/2014)... foam of atom-thick sheets can be made to any ... Rice University. , In microscopic images, the foam ... and walls that reinforce each other. The structure consists ... of graphene oxide that self-assemble with the assistance of ... the foam could find use in structural components, as ...
Breaking Biology Technology:USDA Grant Funds Second Phase of Bio-Energy Research Community Economic Development in CT 2USDA Grant Funds Second Phase of Bio-Energy Research Community Economic Development in CT 3SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 2SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 3SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 4Tough foam from tiny sheets 2
... 2012  Argos Therapeutics Inc., today announced that it ... AGS-003-006, a Phase 2 study of its Arcelis™ ... with advanced renal cell carcinoma (RCC). The results ... T cell responses and overall survival. AGS-003 in ...
... DIEGO, Jan. 31, 2012  bioTheranostics, Inc., a bioMerieux ... drive personalized treatment, has introduced a new product ... resistance and pathway interrogation called PRECIS Precision Medicine ... cancer management, partners accurate diagnosis of primary tumor ...
... science world, with the potential to create foldaway mobile phones, ... new finding at the University of Manchester gives graphene,s potential ... for distilling alcohol. In a report published in ... shows that graphene-based membranes are impermeable to all gases and ...
Cached Biology Technology:Argos Therapeutic Arcelis™ Immunotherapy AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival in Phase 2 Study in Patients with Advanced Renal Cell Carcinoma (RCC) 2Argos Therapeutic Arcelis™ Immunotherapy AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival in Phase 2 Study in Patients with Advanced Renal Cell Carcinoma (RCC) 3bioTheranostics Launches Precision Medicine Biomarkers for Tumor Pathway Interrogation 2bioTheranostics Launches Precision Medicine Biomarkers for Tumor Pathway Interrogation 3Supermaterial goes superpermeable 2
(Date:7/30/2014)... changing climate threaten some of the world,s most ... establish seed collections to save the seeds in ... some genetic diversity., For decades, these seed collections ... a one-size-fits-all approach for how many seeds to ... regardless of species, pollination mode, growth habitat and ...
(Date:7/30/2014)... from Bjorn Brembs, professor of neurogenetics at the Institute ... figure allowing readers and reviewers to run the underlying ... important leap forward for scientific publishing, by demonstrating a ... scholarly output. , Figure 3 in fact doesn,t really ... to F1000Research , and the figure is generated ...
(Date:7/30/2014)... injury (SCI), traumatic brain injury (TBI) and peripheral nerve ... learned over the past 30 years regarding both the ... growth, but this large body of information has not ... his team from University of Miami in USA proposed ... consensus is emerging that one contributing factor is a ...
Breaking Biology News(10 mins):Saving seeds the right way can save the world's plants 2F1000Research brings static research figures to life 2
... Hagfish is a strange animal: it feeds by gnawing its way ... 3 days. Scientists at the University of British Columbia (Canada) believe ... inside the carcass to become acidic from the build up of ... is able to cope with environmental conditions of up to 7% ...
... to a low-weight preemie at 24 weeks, exhibited the first-found ... and the amniotic fluid of a woman in preterm labor. ... cannot be cultured and grown in the lab, researchers from ... Department of Obstetrics and Gynecology at MetroHealth Medical Center in ...
... Dr. Peter Sarnow and a team of Stanford University scientists ... named miR-122, in order to replicate in cultured liver cells. ... amount of hepatitis C virus RNA was reduced by approximately ... potential to develop new antiviral agents against hepatitis C, the ...
Cached Biology News:Prenatal nicotine exposure reduces breathing response of newborns... 2Prenatal nicotine exposure reduces breathing response of newborns... 3
Multi-enzyme complex containing a wide range of carbohydrases, including arabanase, cellulase,b-glucanase, hemi-cellulase and xylanase Patent/trademark/license (electronic): A product of Novozyme Cor...
... Biotin Streptavidin-HRP Systems provide rapid, precise ... antigens in frozen or paraffin-embedded tissue, ... systems also facilitate double or triple ... performed simultaneously with primary antibodies of ...
Miscellaneous: Versatile stain for staining RNA (bluish-purple), DNA (blue), proteins (red) and acid polysaccharides Assay: ~ 95 % Suitab tst: differential staining of nucleic acids and prote...
Screening test for the detection of Salmonella sp. by means of DNA amplification, subsequent molecular hybridization and detection on a microtitre plate....
Biology Products: